Medicine and Life Sciences Division

Daniel Scherman scientific contribution concerns bioenergetics, neuropharmacology, gene therapy and bioimagng. Some of his results led bio-imaging agents and natural history of early Parkinson’s disease. More recent discoveries concern gene therapy and genetic vaccination, where he has pioneered physical gene delivery and the concept of biosafe “mini-plasmids” and “minicircles”. Daniel Scherman has funded the “Paris Centre of Pharmaceutical Research” at the Paris Pharmacy Faculty, and of the “Laboratory of Chemical and Biological Tools for Health” (UTCBS). Daniel Scherman has been Committee President of the European Society of Cell and Gene Therapy and President of the Pharmacology and Bio-imaging Section of the French National Center for Scientific Research (CNRS). He has been Scientific Director of the Genethon Laboratory of the Telethon/AFM French Myopathy Association and is expert for H2020 European Committees. Daniel Scherman is author of over 59 articles in reviewed journals and 50 book chapters (h-index 64 and 18,000 citations).